David Rosenbaum

David Rosenbaum currently serves as the Chief Development Officer at Ardelyx. Prior to this, they held various Product Development positions at Fenway Pharmaceuticals, Trine Pharmaceuticals, Phaedrus Pharmaceuticals, and Geltex Pharmaceuticals. David started their career as a Senior Consultant at Arthur D. Little.

David has over 25 years of experience in the pharmaceutical industry. David is an expert in product development, with a proven track record of successful commercialization of multiple drugs. David has a deep understanding of the drug development process, from early discovery through late-stage clinical development and commercialization.

David has a Bachelor of Science degree in Chemical Engineering from Cornell University.

David Rosenbaum has a Ph.D. in Pharmacology from Boston University School of Medicine, an M.S. in Toxicology from Albany Medical College, and a B.A. in Biology from the University of Pennsylvania.

They work with Justin Renz - CFO, Robert Blanks - Chief Regulatory Affairs & QA Officer, and Elizabeth Grammer - Chief Legal & Administrative Officer. Their manager is Mike Raab, President & CEO.